サマリー

欧州の線維性疾患治療市場は、2023年から2030年の予測期間に6.0%の大幅なCAGRを記録すると予測されます。この新しい市場レポートは、歴史的な年2021年のデータを含み、計算の基準年は2022年で、予測期間は2023年から2030年です。
市場セグメンテーションです：
欧州線維性疾患治療市場：治療法別（投薬、臓器移植、酸素療法、その他）、用途別（特発性肺線維症、肝硬変、腎線維症、皮膚線維症、その他）、エンドユーザー（病院、専門クリニック、学術・研究機関、その他）、流通チャネル（病院薬局、小売薬局、その他）、国（ドイツ、フランス、U.K．イタリア、スペイン、オランダ、ロシア、スイス、トルコ、ハンガリー、リトアニア、オーストリア、アイルランド、ノルウェー、ポーランド、その他のヨーロッパ地域）産業動向と2030年までの予測

欧州の線維性疾患治療市場の成長に寄与する主な要因としては、以下のものが挙げられます：

- 線維症治療における技術的進歩
- たばこを吸う人の増加

市場プレイヤー
欧州の線維性疾患治療市場における主要な市場プレイヤーを以下に示します：

- ベーリンガーインゲルハイムインターナショナルGmbH
- アッヴィー社（AbbVie Inc.
- レドックス・ファーマ・ピーエルシー
- ブリストル・マイヤーズ スクイブ・カンパニー
- ギリアド・サイエンシズ社（Gilead Sciences, Inc.
- キターバイオテック S.R.L.
- ヴェローナ・ファーマ・ピーエルシー
- インターセプト・ファーマシューティカルズ・インク
- ファーマクシス・リミテッド
- テバ・ファーマシューティカル・インダストリーズ・リミテッド
- サンド・インターナショナルGmbH

ページTOPに戻る

目次

TABLE OF CONTENTS
1 INTRODUCTION 33
1.1 OBJECTIVES OF THE STUDY 33
1.2 MARKET DEFINITION 33
1.3 OVERVIEW OF THE EUROPE FIBROTIC DISEASES TREATMENT MARKET 33
1.4 LIMITATIONS 35
1.5 MARKETS COVERED 35
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 CURRENCY AND PRICING 39
2.5 DBMR TRIPOD DATA VALIDATION MODEL 40
2.6 MULTIVARIATE MODELLING 43
2.7 TREATMENT TYPE LIFELINE CURVE 43
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 44
2.9 DBMR MARKET POSITION GRID 45
2.10 MARKET END USER COVERAGE GRID 46
2.11 VENDOR SHARE ANALYSIS 47
2.12 SECONDARY SOURCES 48
2.13 ASSUMPTIONS 48
3 EXECUTIVE SUMMARY 49
4 PREMIUM INSIGHTS 51
4.1 PORTER'S 5 FORCES 52
4.2 PESTEL ANALYSIS 53
5 EPIDEMIOLOGY 54
5.1 INCIDENCE OF ALL BY GENDER 54
5.2 TREATMENT RATE 54
5.3 MORTALITY RATE 54
5.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL 55
5.5 PATIENT TREATMENT SUCCESS RATE 55
6 INDUSTRY INSIGHTS 56
6.1 PATENT ANALYSIS 56
6.2 DRUG TREATMENT RATE BY MATURED MARKETS 56
6.3 DEMOGRAPHIC TRENDS: IMPACTS ON ALL INCIDENCE RATE 56
6.4 KEY PRICING STRATEGIES 57
6.5 KEY PATIENT ENROLLMENT STRATEGIES 58
7 MERGERS AND ACQUISITIONS 60
7.1 LICENSING: 60
7.2 COMMERCIALIZATION AGREEMENTS 60
8 PIPELINE ANALYSIS 61
8.1 PHASE 1 61
8.2 PHASE 2 61
8.3 PHASE 3 61
9 EUROPE FIBROTIC DISEASES TREATMENT MARKET, REGULATIONS 62
9.1 FDA APPROVALS 62
9.2 EMA APPROVALS 63
10 MARKET OVERVIEW 64
10.1 DRIVERS 66
10.1.1 RISING PREVALENCE OF FIBROTIC DISEASES 66
10.1.2 INCREASE IN THE NUMBER OF PEOPLE SMOKING CIGARETTES 66
10.1.3 TECHNOLOGICAL ADVANCEMENT IN THE TREATMENT OF FIBROSIS DISEASES 67
10.2 RESTRAINTS 67
10.2.1 HIGH COST OF MEDICATION AND TREATMENTS 67
10.2.2 LACK OF EFFECTIVE BIOMARKERS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION AND MONITORING OF FIBROTIC DISEASES 67
10.3 OPPORTUNITIES 68
10.3.1 RISING RESEARCH AND DEVELOPMENT ACTIVITIES 68
10.3.2 DEVELOPMENT OF NEW AND MORE EFFECTIVE THERAPIES FOR FIBROTIC DISEASES 68
10.4 CHALLENGES 69
10.4.1 THE COMPLEX AND MULTIFACTORIAL NATURE OF FIBROTIC DISEASES. 69
10.4.2 HIGH RATE OF FAILURE IN CLINICAL TRIALS FOR FIBROTIC DISEASES, WHICH CAN RESULT IN SIGNIFICANT COSTS AND DELAYS IN DRUG DEVELOPMENT 69
11 EUROPE FIBROTIC DISEASES TREATMENT MARKET: BY TREATMENT 70
11.1 OVERVIEW 71
11.2 MEDICATION 73
11.2.1 INTEDANIB (OFEV) 74
11.2.2 PIRFENIDONE (ESBRIET) 74
11.3 ORGAN TRANSPLANTATION 74
11.4 OXYGEN THERAPY 75
11.5 OTHERS 76
12 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION 77
12.1 OVERVIEW 78
12.2 IDIOPATHIC PULMONARY FIBROSIS 81
12.3 HEPATIC CIRRHOSIS 81
12.4 RENAL FIBROSIS 82
12.5 CUTANEOUS FIBROSIS 83
12.6 OTHERS 84
13 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER 85
13.1 OVERVIEW 86
13.2 HOSPITALS 89
13.3 SPECIALTY CLINICS 90
13.4 ACADEMIC AND RESEARCH INSTITUTES 90
13.5 OTHERS 91
14 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL 92
14.1 OVERVIEW 93
14.2 HOSPITAL PHARMACY 96
14.3 RETAIL PHARMACY 96
14.4 OTHERS 97
15 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY REGION 98
15.1 EUROPE 99
15.1.1 GERMANY 106
15.1.2 FRANCE 108
15.1.3 U.K. 110
15.1.4 ITALY 112
15.1.5 SPAIN 114
15.1.6 RUSSIA 116
15.1.7 TURKEY 118
15.1.8 NETHERLANDS 120
15.1.9 SWITZERLAND 122
15.1.10 HUNGARY 124
15.1.11 LITHUANIA 126
15.1.12 AUSTRIA 128
15.1.13 IRELAND 130
15.1.14 NORWAY 132
15.1.15 POLAND 134
15.1.16 REST OF EUROPE 136
16 EUROPE FIBROTIC DISEASES TREATMENT MARKET, COMPANY LANDSCAPE 137
16.1 COMPANY SHARE ANALYSIS: EUROPE 137
17 SWOT ANALYSIS 138
18 COMPANY PROFILE 139
18.1 BOEHRINGER INGELHEIM INTERNATIONAL GMBH 139
18.1.1 COMPANY SNAPSHOT 139
18.1.2 REVENUE ANALYSIS 139
18.1.3 COMPANY SHARE ANALYSIS 140
18.1.4 PRODUCT PORTFOLIO 140
18.1.5 RECENT DEVELOPMENTS 140
18.2 GENENTECH, INC. 141
18.2.1 COMPANY SNAPSHOT 141
18.2.2 COMPANY SHARE ANALYSIS 141
18.2.3 PRODUCT PORTFOLIO 142
18.2.4 RECENT DEVELOPMENTS 142
18.3 SANDOZ INTERNATIONAL GMBH 143
18.3.1 COMPANY SNAPSHOT 143
18.3.2 COMPANY SHARE ANALYSIS 143
18.3.3 PRODUCT PORTFOLIO 144
18.3.4 RECENT DEVELOPMENTS 144
18.4 TEVA PHARMACEUTICAL INDUSTRIES LTD. 145
18.4.1 COMPANY SNAPSHOT 145
18.4.2 REVENUE ANALYSIS 145
18.4.3 COMPANY SHARE ANALYSIS 146
18.4.4 PRODUCT PORTFOLIO 146
18.4.5 RECENT DEVELOPMENTS 146
18.5 ACCORD HEALTHCARE U.S. 147
18.5.1 COMPANY SNAPSHOT 147
18.5.2 COMPANY SHARE ANALYSIS 147
18.5.3 PRODUCT PORTFOLIO 148
18.5.4 RECENT DEVELOPMENTS 148
18.6 ABBVIE INC. 149
18.6.1 COMPANY SNAPSHOT 149
18.6.2 REVENUE ANALYSIS 149
18.6.3 PRODUCT PORTFOLIO 150
18.6.4 RECENT DEVELOPMENTS 150
18.7 ALPINE IMMUNE SCIENCES 151
18.7.1 COMPANY SNAPSHOT 151
18.7.2 REVENUE ANALYSIS 151
18.7.3 PRODUCT PORTFOLIO 152
18.7.4 RECENT DEVELOPMENTS 152
18.8 BELLBROOK LABS 153
18.8.1 COMPANY SNAPSHOT 153
18.8.2 PRODUCT PORTFOLIO 153
18.8.3 RECENT DEVELOPMENTS 153
18.9 BIOMX 154
18.9.1 COMPANY SNAPSHOT 154
18.9.2 REVENUE ANALYSIS 154
18.9.3 PRODUCT PORTFOLIO 155
18.9.4 RECENT DEVELOPMENTS 155
18.10 BRISTOL-MYERS SQUIBB COMPANY 156
18.10.1 COMPANY SNAPSHOT 156
18.10.2 REVENUE ANALYSIS 156
18.10.3 PRODUCT PORTFOLIO 157
18.10.4 RECENT DEVELOPMENTS 157
18.11 CAMBER PHARMACEUTICALS, INC. 158
18.11.1 COMPANY SNAPSHOT 158
18.11.2 PRODUCT PORTFOLIO 158
18.11.3 RECENT DEVELOPMENTS 158
18.12 ENVEDA 159
18.12.1 COMPANY SNAPSHOT 159
18.12.2 PRODUCT PORTFOLIO 159
18.12.3 RECENT DEVELOPMENTS 159
18.13 GILEAD SCIENCES, INC. 160
18.13.1 COMPANY SNAPSHOT 160
18.13.2 REVENUE ANALYSIS 160
18.13.3 PRODUCT PORTFOLIO 161
18.13.4 RECENT DEVELOPMENTS 161
18.14 INTERCEPT PHARMACEUTICALS, INC. 162
18.14.1 COMPANY SNAPSHOT 162
18.14.2 REVENUE ANALYSIS 162
18.14.3 PRODUCT PORTFOLIO 163
18.14.4 RECENT DEVELOPMENTS 163
18.15 KITHER BIOTECH S.R.L. 164
18.15.1 COMPANY SNAPSHOT 164
18.15.2 PRODUCT PORTFOLIO 164
18.15.3 RECENT DEVELOPMENTS 164
18.16 PHARMAXIS LTD 165
18.16.1 COMPANY SNAPSHOT 165
18.16.2 REVENUE ANALYSIS 165
18.16.3 PRODUCT PORTFOLIO 166
18.16.4 RECENT DEVELOPMENTS 166
18.17 REDX PHARMA PLC. 167
18.17.1 COMPANY SNAPSHOT 167
18.17.2 REVENUE ANALYSIS 167
18.17.3 PRODUCT PORTFOLIO 168
18.17.4 RECENT DEVELOPMENTS 168
18.18 VERONA PHARMA PLC 169
18.18.1 COMPANY SNAPSHOT 169
18.18.2 REVENUE ANALYSIS 169
18.18.3 PRODUCT PORTFOLIO 170
18.18.4 RECENT DEVELOPMENTS 170
19 QUESTIONNAIRE 171
20 RELATED REPORTS 174

ページTOPに戻る

図表リスト

LIST OF TABLES
TABLE 1 EUROPE FIBROTIC DISEASES TREATMENT MARKET, PIPELINE ANALYSIS 47
TABLE 2 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 59
TABLE 3 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 60
TABLE 4 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 60
TABLE 5 EUROPE ORGAN TRANSPLANTATION IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 61
TABLE 6 EUROPE OXYGEN THERAPY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 62
TABLE 7 EUROPE OTHER IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 62
TABLE 8 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 66
TABLE 9 EUROPE IDIOPATHIC PULMONARY FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 67
TABLE 10 EUROPE HEPATIC CIRRHOSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 68
TABLE 11 EUROPE RENAL FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 12 EUROPE CUTANEOUS FIBROSIS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 69
TABLE 13 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 70
TABLE 14 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 74
TABLE 15 EUROPE HOSPITALS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 75
TABLE 16 EUROPE SPECIALTY CLINICS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 76
TABLE 17 EUROPE ACADEMIC AND RESEARCH INSTITUTES IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 18 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 77
TABLE 19 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 81
TABLE 20 EUROPE HOSPITAL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 82
TABLE 21 EUROPE RETAIL PHARMACY IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 22 EUROPE OTHERS IN FIBROTIC DISEASES TREATMENT MARKET, BY REGION, 2021-2030 (USD THOUSAND) 83
TABLE 23 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY COUNTRY, 2021-2030 (USD THOUSAND) 89
TABLE 24 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 89
TABLE 25 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 89
TABLE 26 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 90
TABLE 27 EUROPE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 90
TABLE 28 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 90
TABLE 29 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 90
TABLE 30 EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 91
TABLE 31 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 92
TABLE 32 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 92
TABLE 33 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 92
TABLE 34 GERMANY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 92
TABLE 35 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 93
TABLE 36 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 93
TABLE 37 GERMANY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 93
TABLE 38 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 94
TABLE 39 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 94
TABLE 40 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 94
TABLE 41 FRANCE MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 94
TABLE 42 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 95
TABLE 43 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 95
TABLE 44 FRANCE FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 95
TABLE 45 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 96
TABLE 46 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 96
TABLE 47 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 96
TABLE 48 U.K. MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 96
TABLE 49 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 97
TABLE 50 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 97
TABLE 51 U.K. FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 97
TABLE 52 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 98
TABLE 53 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 98
TABLE 54 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 98
TABLE 55 ITALY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 98
TABLE 56 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 99
TABLE 57 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 99
TABLE 58 ITALY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 99
TABLE 59 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 100
TABLE 60 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 100
TABLE 61 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 100
TABLE 62 SPAIN MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 100
TABLE 63 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 101
TABLE 64 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 101
TABLE 65 SPAIN FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 101
TABLE 66 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 102
TABLE 67 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 102
TABLE 68 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 102
TABLE 69 RUSSIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 102
TABLE 70 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 103
TABLE 71 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 103
TABLE 72 RUSSIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 103
TABLE 73 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 104
TABLE 74 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 104
TABLE 75 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 104
TABLE 76 TURKEY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 104
TABLE 77 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 105
TABLE 78 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 105
TABLE 79 TURKEY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 105
TABLE 80 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 106
TABLE 81 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 106
TABLE 82 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 106
TABLE 83 NETHERLANDS MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 106
TABLE 84 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 107
TABLE 85 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 107
TABLE 86 NETHERLANDS FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 107
TABLE 87 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 108
TABLE 88 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 108
TABLE 89 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 108
TABLE 90 SWITZERLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 108
TABLE 91 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 109
TABLE 92 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 109
TABLE 93 SWITZERLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 109
TABLE 94 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 110
TABLE 95 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 110
TABLE 96 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 110
TABLE 97 HUNGARY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 110
TABLE 98 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 111
TABLE 99 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 111
TABLE 100 HUNGARY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 111
TABLE 101 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 112
TABLE 102 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 112
TABLE 103 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 112
TABLE 104 LITHUANIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 112
TABLE 105 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 113
TABLE 106 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 113
TABLE 107 LITHUANIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 113
TABLE 108 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 114
TABLE 109 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 114
TABLE 110 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 114
TABLE 111 AUSTRIA MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 114
TABLE 112 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 115
TABLE 113 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 115
TABLE 114 AUSTRIA FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 115
TABLE 115 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 116
TABLE 116 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 116
TABLE 117 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 116
TABLE 118 IRELAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 116
TABLE 119 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 117
TABLE 120 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 117
TABLE 121 IRELAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 117
TABLE 122 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 118
TABLE 123 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 118
TABLE 124 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 118
TABLE 125 NORWAY MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 118
TABLE 126 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 119
TABLE 127 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 119
TABLE 128 NORWAY FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 119
TABLE 129 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 120
TABLE 130 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (USD THOUSAND) 120
TABLE 131 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (VOLUME) 120
TABLE 132 POLAND MEDICATION IN FIBROTIC DISEASES TREATMENT MARKET, BY PRODUCTS, 2021-2030 (ASP) 120
TABLE 133 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY APPLICATION, 2021-2030 (USD THOUSAND) 121
TABLE 134 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY END USER, 2021-2030 (USD THOUSAND) 121
TABLE 135 POLAND FIBROTIC DISEASES TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2030 (USD THOUSAND) 121
TABLE 136 REST OF EUROPE FIBROTIC DISEASES TREATMENT MARKET, BY TREATMENT, 2021-2030 (USD THOUSAND) 122